Co-Authors
This is a "connection" page, showing publications co-authored by Paolo Ascierto and Vincenzo Montesarchio.
Connection Strength
1.404
-
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020 08; 8(2).
Score: 0.895
-
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020 05; 8(1).
Score: 0.220
-
Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-a Expression. Biology (Basel). 2021 Aug 01; 10(8).
Score: 0.060
-
Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave. J Transl Med. 2021 03 02; 19(1):93.
Score: 0.058
-
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020 10 21; 18(1):405.
Score: 0.057
-
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. Contemp Clin Trials. 2020 11; 98:106165.
Score: 0.057
-
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. J Immunother Cancer. 2020 10; 8(2).
Score: 0.057